Saudi Journal of Biological Sciences (Mar 2020)

A novel bivalent Pasteurellosis-RHD vaccine candidate adjuvanted with Montanide ISA70 protects rabbits from lethal challenge

  • Jakeen K. El-Jakee,
  • Ihab M. Moussa,
  • Mai S. Omran,
  • Basem M. Ahmed,
  • Mahmoud A. Elgamal,
  • Hassan A. Hemeg,
  • Ayman S. Mubarak,
  • Khalid S. Al-Maary,
  • Saleh A. Kabli,
  • Sherif A. Marouf,
  • Jwaher Haji Alhaaji

Journal volume & issue
Vol. 27, no. 3
pp. 996 – 1001

Abstract

Read online

In the present study, a bivalent vaccine against Pasteurella multocida and rabbit hemorrhagic disease virus (RHDV) was formulated with Montanide™ ISA70 oil adjuvant (Seppic, Paris, France). Its efficacy was evaluated and compared to similar monovalent preparations and commercially available monovalent vaccines. White new Zeeland rabbit groups (n = 10) received 2 successive doses of the tested vaccines and were challenged 2 weeks after 2nd dose with Pasteurella multocida and RHDV or either pathogens according to their vaccination schedule. Challenged not-vaccinated group of rabbits (n = 10) was included as a control. The bivalent and monovalent ISA70 preparations were found stable, safe, sterile, pure and of low viscosity. Group 3 (GP3) which received bivalent vaccine showed the highest antibody geometric mean titers against Pasteurella multocida and RHDV evaluated by ELISA and hemagglutination inhibition (HI) respectively. Following virulent challenge; Gp3 rabbits were 90% protected from challenge over other groups that showed 80% protection. Detection of either pathogen in the livers of dead and euthanized rabbits had failed except for non-vaccinated controls. The bivalent vaccine candidate was fully protective. Immunization against both pathogens can be achieved by single vaccination. Keywords: Pasteurellosis, RHDV, Vaccine, Rabbits, Bivalent, Montanide ISA70